Table 1.
Baseline Characteristics of Study Patients (n=524)
| Characteristic | Value |
|---|---|
| Age, yr | 46.2±12.2 |
| Male sex | 340 (64.9) |
| BMI, kg/m2 | 23.9±3.1 |
| Diabetes | 59 (11.3) |
| Alcohol consumption (≥20 g/day) | 135 (25.8) |
| Family history of HCC | 43/422 (10.2) |
| Coinfection with HCV | 4/467 (0.9) |
| HBeAg positive | 360 (68.7) |
| Cirrhosis | 194 (37.0) |
| Platelets, ×103/mm3 | 154.5±71.8 |
| PT (INR) | 1.1±0.2 |
| Serum AST, IU/L | 125.9±193.1 |
| Serum ALT, IU/L | 157.6±195.0 |
| Total bilirubin, mg/dL | 1.4±1.8 |
| Albumin, g/dL | 3.9±0.5 |
| Creatinine, mg/dL | 0.8±0.4 |
| Serum HBV DNA, log10 IU/mL | 6.4±1.2 |
| Child-Pugh score | 5.5±1.1 |
| Child-Pugh class A/B/C | 450 (85.9)/64 (12.2)/10 (1.9) |
| MELD score | 5.6±4.94 |
| Initial treatment NA | |
| LAM | 293 (55.9) |
| CLV | 70 (13.4) |
| ETV | 161 (30.7) |
| Median follow-up duration (range), mo | 48 (8–60) |
Data are presented mean±SD or number (%) unless otherwise indicated.
BMI, body mass index; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBeAg, hepatitis B e antigen; PT (INR), prothrombin time (international normalized ratio); AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV, hepatitis B virus; MELD, model for end-stage liver disease; NA, nucleos(t)ide analog; LAM, lamivudine; CLV, clevudine; ETV, entecavir.